An enhancer demethylator phenotype converged to immune dysfunction and resistance to immune checkpoint inhibitors in clear-cell renal cell carcinomas.

Date publication

novembre 2022

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DAVIDSON Irwin , Pr LANG Hervé , Dr LINDNER Véronique , Pr MALOUF Gabriel , Dr TRICARD Thibault

Tous les auteurs :
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Roupret M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36374555

Résumé

Immune checkpoint inhibitors have revolutionized the treatment of patients with clear-cell renal carcinomas (ccRCC). Although, analyses of transcriptome, genetic alterations, and the tumor microenvironment have shed light into mechanisms of response and resistance to these agents, the role of epigenetic alterations in this process remains fully unknown.

Référence

Clin Cancer Res. 2022 11 14;: